ACE2-Ang (1-7) axis is induced in pressure overloaded rat model

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 2, 2015, Pages 1443-1450

  Liang, Bai ^a,b,c   Li, Yongqin ^a   Han, Zhenhua ^a   Xue, Jiahong ^a   Zhang, Yan ^a   Jia, Shan ^a   Wang, Congxia ^a  

^a THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

ACE2; Ang (1 7); Pressure overload induced heart failure; Rat

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN I (1-7); DIPEPTIDYL CARBOXYPEPTIDASE; PEPTIDE FRAGMENT;

ANIMAL; BIOSYNTHESIS; CARDIAC MUSCLE; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART FAILURE; MALE; METABOLISM; PATHOPHYSIOLOGY; RAT; REAL TIME POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANGIOTENSIN I; ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEART FAILURE; MALE; MYOCARDIUM; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84928150213     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, Tikellis C, Grant SL, Lew RA, Smith AI, Cooper ME and Johnston CI. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 2005; 26: 369-75; discussion 22-4.
2. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y and Penninger JM. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-8.
3. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE and Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-9.
4. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK and Katovich MJ. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 2007; 292: H736-42.
5. Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, Ferrario CM and Raizada MK. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 2005; 90: 783-90.
6. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX and Greenberg BH. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 2005; 289: H2356-63.
7. Langeveld B, van Gilst WH, Tio RA, Zijlstra F and Roks AJ. Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension 2005; 45: 138-41.
8. Mehta PK and Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292: C82-97.
9. Mercure C, Yogi A, Callera GE, Aranha AB, Bader M, Ferreira AJ, Santos RA, Walther T, Touyz RM and Reudelhuber TL. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 2008; 103: 1319-26.
10. Ohtsuki M, Morimoto S, Izawa H, Ismail TF, Ishibashi-Ueda H, Kato Y, Horii T, Isomura T, Suma H, Nomura M, Hishida H, Kurahashi H and Ozaki Y. Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure. Int J Cardiol 145: 333-4.
11. Oudit GY, Crackower MA, Backx PH and Penninger JM. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med 2003; 13: 93-101.
12. Oudit GY, Kassiri Z, Patel MP, Chappell M, Butany J, Backx PH, Tsushima RG, Scholey JW, Khokha R and Penninger JM. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res 2007; 75: 29-39.
13. Paul M, Poyan Mehr A and Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747-803.
14. Santos RA and Ferreira AJ. Angiotensin-(1-7) and the renin-angiotensin system. Curr Opin Nephrol Hypertens 2007; 16: 122-8.
15. Santos RA, Ferreira AJ and Simões E Silva AC. Recent advances in the angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis. Exp Physiol 2008; 93: 519-27.
16. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89: 3A-9A; discussion 10A.
17. Wang J and Nagueh SF. Current perspectives on cardiac function in patients with diastolic heart failure. Circulation 2009; 119: 1146-57.
18. Weber KT and Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-65.
19. Zaman MA, Oparil S and Calhoun DA. Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov 2002; 1: 621-36.
20. Zhao YX, Yin HQ, Yu QT, Qiao Y, Dai HY, Zhang MX, Zhang L, Liu YF, Wang LC, Liu de S, Deng BP, Zhang YH, Pan CM, Song HD, Qu X, Jiang H, Liu CX, Lu XT, Liu B, Gao F and Dong B. ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction. Hum Gene Ther 21: 1545-54.
21. Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, Loibner H, Wang XH, Penninger JM, Kassiri Z and Oudit GY. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 2010; 122: 717-28, 18 p following 28.
22. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR and Canver CC. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation 2003; 108: 1707-12.
23. Zucker IH, Xiao L and Haack KK. The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure. Clin Sci (Lond) 2014; 126: 695-706.